MediPharm Labs has successfully completed its second set of export shipments of medical cannabis concentrate, which were 137% greater in volume compared to its first export into Australia in June 2019. "Through its wholly owned subsidiary, MediPharm Labs the Company received its second set of export permits from Health Canada to ship an increased volume of medical cannabis concentrates from Canada to Australia," the team with the company explains. "Prior to the shipment, the Australian Government’s Office of Drug Control Section also issued a second set of import permits."
“We are pleased to have completed our second set of shipments of medical cannabis concentrate into Australia in the third quarter as we look to participate in addressing the growing Australian medical patient demand,” said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “As international demand for purified cannabis concentrates continues to grow, we have focused on expanding our global supply chain and our international presence, including through our recently announced supply agreement for the German medical market. We have also focused on meeting diverse international regulatory and permitting requirements, including working towards our EU GMP, to grow export volumes of MediPharm Labs’ private-label concentrates.”
For more information:
MediPharm Labs
151 John Street, Barrie
+1 705 719 7425
medipharmlabs.com